The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
 
Kevin Kalinsky
Stock and Other Ownership Interests - Array BioPharma (I); GRAIL (I); Pfizer (I)
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Cyclacel; Eisai; Genentech/Roche; immunomedics; Ipsen; Lilly; Merck; Novartis; Oncosec; pfizer; Seagen
Speakers' Bureau - Lilly
Research Funding - Acetylon Pharmaceuticals (Inst); Amgen (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Zeno Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Pfizer
Other Relationship - Genentech; Immunomedics
 
Mafalda Oliveira
Honoraria - Novartis; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Puma Biotechnology; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Novartis (Inst); Piqur (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Roche
 
Tiffany A. Traina
Consulting or Advisory Role - Aduro Biotech; Advaxis; AstraZeneca; Athenex; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genomic Health; Halozyme; Immunomedics; Innocrin Pharma; Ionis Pharmaceuticals; Merck; Pfizer; Puma Biotechnology; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Carrick Pharm (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Innocrin Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Sara M. Tolaney
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bristol-Myers Squibb; Celldex; Certara Inc; CytomX Therapeutics; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Immunomedics/Gilead; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; Paxman; Pfizer; Puma Biotechnology; Samsung Bioepis; Sanofi; Seagen; Silverback Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celldex; Eisai; Genentech/Roche; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology
 
Delphine Loirat
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Immunomedics; MSD Oncology; Novartis; Pfizer; Roche
Expert Testimony - Amgen; Roche
Travel, Accommodations, Expenses - AstraZeneca; MSD; Pfizer; Roche
 
Kevin Punie
Honoraria - Lilly (Inst); Lilly (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer; Pfizer (Inst); Pfizer (Inst); Roche (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Lilly (Inst); Lilly (Inst); Novartis; Novartis; Novartis; Novartis (Inst); Novartis (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Teva (Inst); Vifor Pharma (Inst)
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; PharmaMar; Roche; Roche; Roche; Roche
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Filipa Lynce
Consulting or Advisory Role - ASCO; AstraZeneca; Bristol-Myers Squibb; Pfizer/EMD Serono
Research Funding - Bristol-Myers Squibb; Chugai Pharma USA (Inst); Immunomedics (Inst); Inivata (Inst); Pfizer; Tesaro (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech
 
Erika P. Hamilton
Consulting or Advisory Role - Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Akeso Biopharma (Inst); Amgen (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Polyphor (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Rita Nanda
Consulting or Advisory Role - Aduro Biotech; Athenex; Daiichi Sankyo; Genentech/Roche; Immunomedics; ION Pharma; Macrogenics; Merck; Pfizer; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Other Relationship - G1 Therapeutics
 
Lowell L. Hart
Honoraria - AstraZeneca; Daiichi Sankyo; G1 Therapeutics; Karyopharm Therapeutics; Novartis; Seagen; Veracyte
Consulting or Advisory Role - Amgen; G1 Therapeutics; Genentech/Roche; Merck; Seagen
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Genentech; Lilly; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Novartis (Inst); Seagen (Inst)
 
Paul D. Richards
No Relationships to Disclose
 
Zulfiqar A. Malik
No Relationships to Disclose
 
Hope S. Rugo
Honoraria - Mylan; Puma Biotechnology
Consulting or Advisory Role - Samsung
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; Pfizer
 
Veronique Dieras
Honoraria - Abbvie; AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Seagen
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Seagen
Speakers' Bureau - Abbvie; AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Seagen
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Seagen
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Quan Hong
Employment - Gilead Sciences; Gilead Sciences; Immunomedics
Leadership - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
Martin Sebastian Olivo
Employment - Immunomedics/Gilead
Leadership - Immunomedics/Gilead
Stock and Other Ownership Interests - Immunomedics/Gilead
Travel, Accommodations, Expenses - Immunomedics/Gilead
 
Loretta Itri
Employment - Immunomedics
Leadership - Immunomedics
Stock and Other Ownership Interests - Immunomedics
Consulting or Advisory Role - Immunomedics
Travel, Accommodations, Expenses - Immunomedics
 
Sibylle Loibl
Honoraria - Chugai Pharma
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Medscape (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Puma Biotechnology (Inst); Roche (Inst); Samsung (Inst); Seagen (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Immunomedics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending EP14153692.0 (Inst)